- Empagliflozin: Basic clinical characteristics2015 | First Faculty of Medicine
- Empagliflozin - new SGLT2 inhibitor for diabetes mellitus treatment2014 | First Faculty of Medicine, Third Faculty of Medicine
- Renal protective effect of empagliflozin2016 | Second Faculty of Medicine
- Modern antidiabetics in synergy: fixed dose combination empagliflozin/linagliptin2017 | First Faculty of Medicine
- Fixed combination of empagliflozin and metformin in therapy of type 2 diabetes mellitus2015 | First Faculty of Medicine
- Empagliflozin and current position SGLT2 inhibitors in the treatment of type 2 diabetes2015 | First Faculty of Medicine
- Empagliflozin: Another quiet revolutionaries - editorial2014 | Second Faculty of Medicine
- Empagliflozin - the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type2015 | First Faculty of Medicine, Third Faculty of Medicine
- What connects SGLT2 inhibitors, diabetes mellitus, heart failure and empagliflozin?2022 | First Faculty of Medicine
- Účinek empagliflozinu na snížení kardiovaskulární mortality diabetiků by mohl být zprostředkován snížením plasmatického objemu2018 | Second Faculty of Medicine
- Empagliflozin zpomaluje progresi renální insuficience u širokého spektra pacientů s chronickým onemocněním ledvin2022 | First Faculty of Medicine
- Importance of EMPA-REG OUTCOME Trial to the Clinical Care and Research2017 | First Faculty of Medicine
- Fixní kombinace empagliflozinu s metforminem2016 | Third Faculty of Medicine
- Mortalita a morbidita u pacientů s renálním onemocněním při léčbě empagliflozinem a bezpečnost empagliflozinu u pacientů s postižením periferních tepen dolních končetin ve studii EMPA-REG OUTCOME (komentář)2018 | First Faculty of Medicine
- Gliflozins slow down the progression of diabetic kidney disease2017 | First Faculty of Medicine
- Bezpečnost empagliflozinu při chronickém onemocnění ledvin2022 | First Faculty of Medicine
- Gliflozins and heart failure - what is and will be new?2021 | First Faculty of Medicine
- Nefroprotektivní účinek empagliflozinu2017 | First Faculty of Medicine
- Antidiabetic drugs of interest2016 | Second Faculty of Medicine
- Empagliflozin u pacientů s chronickým onemocněním ledvin - studie EMPA-KIDNEY2023 | Third Faculty of Medicine
- Treatment of diabetes and cardiovascular risk: the end of a dogma in the treatment of type 2 diabetes2016 | First Faculty of Medicine
- Novel antidiabetics and progression of diabetic nephropathy +12018 | First Faculty of Medicine
- Využití empagliflozinu u kardiorenálního syndromu2022 | First Faculty of Medicine
- Kyselina močová ve vztahu ke kardiorenální problematice u diabetiků: snížení koncentrace kyseliny močové jako přínos léčby empagliflozinem2020 | First Faculty of Medicine
- Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress2021 | First Faculty of Medicine
- Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease2022 | Third Faculty of Medicine
- Kardiovaskulární bezpečnost empagliflozinu - komentář s diskusí2016 | First Faculty of Medicine
- Empagliflozin zpomaluje progresi onemocnění ledvin u pacientů s diabetes mellitus 2. typu : Komentář2016 | First Faculty of Medicine
- CVD_REAL: The Real Benefit of Gliglozins for the Treatment of Type 2 Diabetes in Common Clinical Practice2018 | Faculty of Medicine in Hradec Králové